Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WellbutrinXL · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Group 1 | EXPERIMENTAL | Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks. |
| Treatment Group 2 | EXPERIMENTAL | Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. |
| Name | Type | Description |
|---|---|---|
| WellbutrinXL | DRUG | WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg. |
| placebo | DRUG | Matching placebo tablets to WELLBUTRIN XL. |
Inclusion Criteria: * Healthy males or females. * Non-smokers * Agree to remain in the clinic for the time defined in the protocol. * Normal ECG. Exclusion Criteria: * Any serious medical disorder or condition. * Any history of an endocrine disorder. * Any clinically significant laboratory abnorm...
Top 20 of 29 competitors
Wellbutrin XL is a small molecule drug being studied for Orgasmic Disorder and Depressive Disorder. It is developed by GSK plc. The drug is currently in Phase 2 clinical development for these conditions.
Wellbutrin XL is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is being investigated for use in Orgasmic Disorder and Depressive Disorder.
Wellbutrin XL is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy for the studied indications.
Wellbutrin XL has been studied in clinical trials including NCT00248209, a Phase 2 trial for Female Orgasmic Disorder, and NCT00439868, a Phase 1 trial for Depressive Disorder. Both trials were completed in the United States.
Wellbutrin XL is a brand name for the drug bupropion, which is used to treat depression. However, the specific formulation and delivery mechanism of Wellbutrin XL may differ from other bupropion products.